Physicians treating patients affected by nonmuscle-invasive bladder cancer (NMIBC) have
been in shock during the last six years since manufacturing restrictions on the production of …

The arsenal against different types of cancers has increased impressively in the last decade.
The detailed knowledge of the tumor microenvironment enables it to be manipulated in …

Intravesical Mycobacterium bovis Bacillus Calmette–Guérin (BCG) immunotherapy remains
the gold-standard treatment for non-muscle-invasive bladder cancer patients, even though …

The hydrophobic composition of mycobacterial cell walls leads to the formation of clumps
when attempting to resuspend mycobacteria in aqueous solutions. Such aggregation may …

The standard treatment for high-risk non-muscle invasive bladder cancer (BC) is the
intravesical administration of live Mycobacterium bovis BCG. Previous studies suggest …

Bacillus Calmette-Guérin (BCG) is considered to be a successful biotherapy for treating
bladder cancer (BCa). However, the underlying mechanisms of BCG have not been …

Mycobacterium brumae is a rapid-growing, non-pathogenic Mycobacterium species,
originally isolated from environmental and human samples in Barcelona, Spain …

The most successful immunotherapeutic treatment for nonmuscle invasive bladder cancer
(NMIBC) to date is the intravesical instillation of Mycobacterium bovis bacillus Calmette …

Mycobacteria are the unique group of bacteria that are currently used in antitumoral
immunotherapy. Specifically, intravesical instillation of viable cells of Mycobacterium bovis …

Draft Genome Sequence of Mycobacterium brumae ATCC 51384 | Genome
Announcements CLOSE This Journal Anywhere Enter words / phrases / DOI / ISBN …